Patents by Inventor Maurice V. Cattaneo

Maurice V. Cattaneo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6899107
    Abstract: A method by which immune responses to cortical bone grafts and other substrates (e.g., cement, IPN, etc.) can be minimized and at the same time graft osteoinductive potential can be improved, and improved graft substrate materials are disclosed. The method of the invention provides new types of bone grafts that incorporate into host bone more thoroughly and more rapidly, eliminating long-term complications, such as fracture, non-union, infection, and rejection. In the method of the invention, bone grafts or other substrates are modified to have an osteoinductive surface modification that the recipient's body will accept as its own tissue type and therefore will not reject or otherwise cause to fail. The osteoinductive surface modification comprises a biopolymer matrix coating that is seeded with periosteal cells that have been previously harvested either from the graft recipient or from an allogenic or xenogenic donor source.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: May 31, 2005
    Assignee: Cambridge Scientific, Inc.
    Inventors: Kai-Uwe Lewandrowski, Shrikar Bondre, Debra J. Trantolo, Maurice V. Cattaneo, Joseph D. Gresser, Donald L. Wise
  • Publication number: 20030109934
    Abstract: A method by which immune responses to cortical bone grafts and other substrates (e.g., cement, IPN, etc.) can be minimized and at the same time graft osteoinductive potential can be improved, and improved graft substrate materials are disclosed. The method of the invention provides new types of bone grafts that incorporate into host bone more thoroughly and more rapidly, eliminating long-term complications, such as fracture, non-union, infection, and rejection. In the method of the invention, bone grafts or other substrates are modified to have an osteoinductive surface modification that the recipient's body will accept as its own tissue type and therefore will not reject or otherwise cause to fail. The osteoinductive surface modification comprises a biopolymer matrix coating that is seeded with periosteal cells that have been previously harvested either from the graft recipient or from an allogenic or xenogenic donor source.
    Type: Application
    Filed: December 27, 2002
    Publication date: June 12, 2003
    Applicant: Cambridge Scientific, Inc.
    Inventors: Kai-Uwe Lewandrowski, Shrikar Bondre, Debra J. Trantolo, Maurice V. Cattaneo, Joseph D. Gresser, Donald L. Wise
  • Patent number: 6551355
    Abstract: A method by which immune responses to cortical bone grafts and other substrates (e.g., cement, IPN, etc.) can be minimized and at the same time graft osteoinductive potential can be improved, and improved graft substrate materials are disclosed. The method of the invention provides new types of bone grafts that incorporate into host bone more thoroughly and more rapidly, eliminating long-term complications, such as fracture, non-union, infection, and rejection. In the method of the invention, bone grafts or other substrates are modified to have an osteoinductive surface modification that the recipient's body will accept as its own tissue type and therefore will not reject or otherwise cause to fail. The osteoinductive surface modification comprises a biopolymer matrix coating that is seeded with periosteal cells that have been previously harvested either from the graft recipient or from an allogenic or xenogenic donor source.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: April 22, 2003
    Assignee: Cambridge Scientific, Inc.
    Inventors: Kai-Uwe Lewandrowski, Shrikar Bondre, Debra J. Trantolo, Maurice V. Cattaneo, Joseph D. Gresser, Donald L. Wise
  • Patent number: 5411866
    Abstract: An apparatus and method for measuring glutamine and glucose in certain cell cultures and body fluids in the presence of interfering endogenous compounds e.g. ascorbic acid, uric acid or glutamic acid. Prior to enzymatic degradation and amperometric detection of the products or elements resulting from the degradation, the interfering substances are retained by an anion exchanger disposed upstream of the enzymatic degradation site. The conditions of the method are controlled to utilize the difference of isoelectric points of the measured biosubstance and of the interfering compounds respectively.
    Type: Grant
    Filed: March 30, 1993
    Date of Patent: May 2, 1995
    Assignee: National Research Council of Canada
    Inventors: John H. T. Luong, Keith B. Male, Maurice V. Cattaneo